Pharmaceuticals company Eris Lifesciences announced Q1FY27 results Consolidated Financial Highlights: Total Income for Q1FY27 stood at Rs 875.64 crore, reflecting a YoY growth of 12.88% from Rs 775.69 crore in Q1FY26 and a QoQ growth of 15.40% from Rs 758.79 crore in Q4FY26. Total Revenue from Operations reached Rs 873.25 crore in Q1FY27, representing an increase of 12.97% YoY from Rs 773.00 crore in Q1FY26 and an increase of 15.42% QoQ from Rs 756.56 crore in Q4FY26. Net Profit for the Period was Rs 143.32 crore in Q1FY27, showing a YoY growth of 14.56% compared to Rs 125.10 crore in Q1FY26. However, it experienced a QoQ decline of 48.65% from Rs 279.10 crore in Q4FY26 (noting that Q4FY26 included a significant deferred tax credit). Profit Before Tax (PBT) for Q1FY27 was Rs 179.49 crore, up 11.42% YoY from Rs 161.10 crore in Q1FY26 and up 12.60% QoQ from Rs 159.41 crore in Q4FY26. Total Comprehensive Income for the period stood at Rs 143.38 crore in Q1FY27, compared to Rs 124.53 crore in Q1FY26 and Rs 279.54 crore in Q4FY26. Basic Earnings Per Share (EPS) for Q1FY27 was Rs 10.28, compared to Rs 8.66 in Q1FY26 and Rs 20.60 in Q4FY26. Standalone Financial Highlights: Total Income for Q1FY27 was Rs 470.37 crore, marking a YoY decline of 21.78% from Rs 601.32 crore in Q1FY26, but a QoQ increase of 54.58% from Rs 304.28 crore in Q4FY26. Total Revenue from Operations stood at Rs 443.99 crore in Q1FY27, a YoY decrease of 23.27% from Rs 578.64 crore in Q1FY26 and a QoQ increase of 60.11% from Rs 277.31 crore in Q4FY26. Net Profit for the Period reached Rs 48.30 crore in Q1FY27, a YoY decline of 51.69% compared to Rs 99.99 crore in Q1FY26. On a sequential basis, the company reported a turnaround from a net loss of Rs 8.60 crore in Q4FY26. Profit Before Tax was Rs 64.14 crore in Q1FY27, compared to Rs 156.26 crore in Q1FY26 and a loss of Rs 32.77 crore in Q4FY26. Business Highlights: Dividend: The Board of Directors declared an interim dividend of Rs 7.21/- (721%) per equity share of face value Rs 1/- each for the financial year 2026-27 during its meeting held on May 20, 2026. Business Acquisition: During the year ended March 31, 2026 (FY26), the company completed the acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for Rs 50 crore on a slump sale basis. Corporate Restructuring: A Composite Scheme of Arrangement is in progress involving Eris Therapeutics Limited (ETL), Eris Oaknet Healthcare Private Limited, and Aprica Healthcare Limited to merge their domestic businesses into ETL. Labour Code Impact: The company assessed the impact of the New Labour Codes in FY26, resulting in an incremental expense of Rs 17.24 crore (Consolidated) and Rs 14.67 crore (Standalone) due to changes in the definition of "wages" for gratuity and leave liability. Tax Remeasurement: During FY26, the company remeasured its deferred tax assets and liabilities based on revised tax rates, resulting in a deferred tax credit of Rs 150 crore recognized in the statement of profit and loss. Equity Allotment: The company issued and allotted 35,602 ordinary shares of Rs 1 each under the Employee Stock Option Scheme 2021 during Q1FY27. Result PDF
Pharmaceuticals company Eris Lifesciences announced Q4FY26 & FY26 results Consolidated Financial Highlights: Total Revenue from Operations: Q4FY26: Rs 756.56 crore compared to Rs 705.30 crore in Q4FY25 (YoY growth of ~7.3%). FY26: Rs 3,129.42 crore compared to Rs 2,893.64 crore in FY25 (YoY growth of ~8.1%). Net Profit for the period: Q4FY26: Rs 279.10 crore compared to Rs 102.35 crore in Q4FY25 (YoY growth of ~172.7%). FY26: Rs 647.51 crore compared to Rs 374.67 crore in FY25 (YoY growth of ~72.8%). Standalone Financial Highlights: Total Revenue from Operations: Q4FY26: Rs 277.31 crore compared to Rs 404.77 crore in Q4FY25 (YoY decline of ~31.5%). FY26: Rs 1,821.74 crore compared to Rs 1,697.75 crore in FY25 (YoY growth of ~7.3%). Net Profit for the period: Q4FY26: Net loss of Rs 8.60 crore compared to profit of Rs 30.47 crore in Q4FY25. FY26: Rs 244.05 crore compared to Rs 77.39 crore in FY25 (YoY growth of ~215.3%). Business Highlights: Dividend Declaration: The Board declared an interim dividend of Rs 7.21 per fully paid-up equity share (at the rate of 721%) for the financial year 2026-2027. The record date is May 29, 2026, and payment will be made on or before June 19, 2026. Acquisitions: Swiss Parenteral Limited (SPL): Completed the acquisition of the remaining minority shares on January 16, 2026, making it a wholly-owned subsidiary. Branded Probiotics Business: Completed the acquisition from Velbiom Probiotics Private Limited on March 31, 2026, for a consideration of Rs 50 crore on a slump sale basis. Regulatory/Tax Impact: Due to eligibility for the concessional tax regime from the financial year 2026-27, the Company remeasured deferred tax assets and liabilities, resulting in a deferred tax credit of Rs 150 crore (consolidated) and Rs 18 crore (standalone) recognized in the Statement of Profit and Loss. Exceptional Items: The Company recorded an exceptional item charge of Rs 17.24 crore (consolidated) and Rs 14.67 crore (standalone) in FY26 related to an increase in gratuity and leave liability due to the implementation of the New Labour Codes. Scheme of Arrangement: The Board approved a composite scheme of arrangement to vest the "Domestic Business" of Eris Oaknet Healthcare Private Limited (EOHPL) into Eris Therapeutics Limited (ETL) and the amalgamation of Aprica Healthcare Limited (AHL) with ETL. This is subject to necessary statutory approvals. Result PDF
Pharmaceuticals company Eris Lifesciences announced Q3FY26 results Revenue from operations: Rs 807.45 crore against Rs 727.45 crore during Q3FY25, change 11%. PBT: Rs 145.35 crore against Rs 116.36 crore during Q3FY25, change 25%. PAT: Rs 108.83 crore against Rs 87.06 crore during Q3FY25, change 25%. EPS: Rs 7.32 for Q3FY26. Q3 Capex Rs 78 crore – largely towards Insulin/ GLP-1 and General Injectables Book Tax Rate – 22.5% in Q3 OCF-to-EBIDTA ratio: 50% in Q3-26 vs 120% in Q3-25 Result PDF